Top Startup and Tech Funding News – April 14 2025

It’s Tuesday, April 14, 2026, and we’re back with today’s top startup and tech funding news. Today’s deals show a clear shift in where serious capital is going: into the infrastructure, orchestration layers, and applied systems that will define how AI, automation, and real-world industries operate over the next decade. From optical networking inside AI data centers to agentic software controlling enterprise workflows, investors are backing the layers that sit beneath the hype—and power everything above it.

Large growth rounds and outsized early-stage bets point to rising conviction in AI infrastructure, industrial automation, biotech pipelines, and specialized enterprise platforms. At the same time, capital is flowing into companies solving real-world constraints—transportation throughput, clinical delivery, and commodity risk—where software meets physical systems. Today’s funding cuts across AI, mobility, healthcare, enterprise software, and deep tech, signaling a broader move toward platforms built for scale, reliability, and long-term deployment.

Tech Funding News

Funding Highlights

• Glydways raises $170M Series C for autonomous vehicle guideway networks
• Sygaldry Technologies raises $105M Series A for quantum-accelerated AI server infrastructure
• nEye.ai raises $80M Series C for optical circuit switching in AI data centers
• Adcendo raises $75M Series C to expand clinical ADC pipeline
• Mintlify raises $45M Series B for AI-readable documentation infrastructure
• Bluefish raises $43M Series B for agentic marketing and AI visibility control
• Synera raises $40M Series B for agentic AI in industrial engineering workflows
• Calyxo raises $40M Series F for kidney stone removal commercial expansion
• Spiral Therapeutics raises $27M Series B for inner ear disorder therapeutics
• Pillar raises $20M Seed for automated commodity risk hedging

Investor Activity

Today’s funding reflects strong participation from top-tier venture firms and strategic investors targeting foundational systems across AI, industrial software, and healthcare. Andreessen Horowitz, NEA, and Khosla Ventures were active across enterprise AI and infrastructure layers, while Breakthrough Energy Ventures and major industrial partners backed next-generation compute and energy-adjacent technologies. Strategic corporates—including Suzuki, Capgemini, and Salesforce—played a visible role, signaling continued convergence between venture capital and industry operators. Across sectors, capital is concentrating around platforms that combine technical depth with real-world deployment and defensible market positioning.

Glydways Raises $170M in Series C Funding for Autonomous Vehicle Guideway Networks

Glydways is building a “managed guideway” approach to autonomy: small, dedicated lanes paired with autonomous electric vehicles designed to move people at high throughput without competing for conventional road capacity. The pitch is not a robo-taxi operating in mixed traffic, but a purpose-built network designed for predictable flow and transit-like utilization.

The $170 million Series C round matters because it pushes the company into a commercialization-heavy phase: launching operational pilots, scaling vehicle production with a strategic manufacturing partner, and turning memorandums and infrastructure commitments into public service. In a sector where autonomy timelines often slip when deployments meet permitting and capex reality, this round is structured to fund real-world operations rather than just R&D.

Funding Details:

• Startup: Glydways
• Investors: Co-leads Suzuki Motor Corporation, ACS Group, Khosla Ventures; participation from Mitsui Chemicals, Gates Frontier; new investor Obayashi Corporation
• Amount Raised: $170M
• Total Raised: Well over $250M
• Funding Stage: Series C
• Funding Date: April 14, 2026

Sygaldry Technologies Raises $105M in Series A Funding for Quantum-Accelerated AI Server Infrastructure

Sygaldry is developing quantum-accelerated AI servers designed to run alongside classical data center infrastructure, speeding up selected AI algorithms while improving performance per watt. Rather than treating quantum as a distant replacement for conventional compute, the company is positioning quantum capability as an add-on “in the rack” and building software paths that fit existing AI tooling.

While the Series A closed in March, today’s announcement is the first consolidated confirmation of the capital structure and investor set, bringing clarity to one of the more ambitious “compute beyond GPUs” infrastructure bets. The size and syndicate breadth signal that investors are increasingly willing to fund next-generation hardware narratives when paired with a clear deployment target: the AI data center.

Funding Details:

• Startup: Sygaldry Technologies
• Investors: Lead Breakthrough Energy Ventures; Seed lead Initialized Capital; notable participation from Y Combinator, In-Q-Tel, RRE Ventures (plus additional investors)
• Amount Raised: $105M (Series A)
• Total Raised: $139M (Series A + Seed)
• Funding Stage: Series A
• Funding Date: April 14, 2026

nEye.ai Raises $80M in Series C Funding for Optical Circuit Switching in AI Data Centers

nEye.ai develops optical switching technology to reduce bottlenecks in AI data centers, where the limiting factor is often not just GPU availability but also the speed at which systems move data between compute and memory tiers. The company’s focus—optical circuit switching—targets the networking layer, which increasingly dictates model-training efficiency, utilization, and power draw.

The $80 million Series C is a scale-up round that funds the transition from sophisticated lab-grade photonics into repeatable manufacturing and customer deployments that can survive data center qualification cycles. In the current AI infrastructure buildout, this is the type of “pick-and-shovel” financing that can compound quickly if it becomes part of standard architectures.

Funding Details:

• Startup: nEye.ai
• Investors: Lead Sutter Hill Ventures; participation from CapitalG, Microsoft M12, Socratic Partners
• Amount Raised: $80M
• Total Raised: $152M
• Funding Stage: Series C
• Funding Date: April 14, 2026

Adcendo Raises $75M in Series C Funding for Clinical ADC Pipeline Expansion

Adcendo is a clinical-stage biotech developing antibody-drug conjugates (ADCs), a modality that pairs targeted antibodies with cytotoxic payloads to improve tumor selectivity while mitigating systemic toxicity. Today’s Series C proceeds are earmarked for upcoming clinical milestones across three ADC programs, reflecting a capital plan aligned to data readouts rather than platform expansion alone.

The strategic relevance is twofold: first, ADCs remain one of biotech’s most competitive and capital-intensive categories, raising the bar for differentiated targets and linker/payload design; second, Adcendo’s round is explicitly designed to finance multiple clinical pushes in parallel—an approach that can accelerate learning, but also requires a larger balance sheet and syndicate coordination.

Funding Details:

• Startup: Adcendo
• Investors: Lead Jeito Capital; new investors Vida Ventures, BPI France, EIFO; notable existing investors include RA Capital Management, OrbiMed, Novo Holdings
• Amount Raised: $75M
• Total Raised: $240M (to date)
• Funding Stage: Series C
• Funding Date: April 14, 2026

Mintlify Raises $45M in Series B Funding for AI-Readable Documentation Infrastructure

Mintlify builds a developer documentation platform and is leaning into an emerging shift: documentation and knowledge bases are becoming machine-consumable infrastructure for AI agents, not just human-readable pages. In that framing, accuracy, structure, and retrieval become product surface area—affecting how tools are discovered and used in AI-driven workflows.

The $45 million Series B is significant because it values the “knowledge layer” as a defensible category. This is a bet that documentation will be one of the primary interfaces between software products and agentic systems, and that vendors who own the pipeline from authoring to structured distribution can become embedded in enterprise workflows.

Funding Details:

• Startup: Mintlify
• Investors: Leads Andreessen Horowitz and Salesforce Ventures; participation from Bain Capital Ventures, DST Global, HubSpot Ventures, Y Combinator (plus additional investors)
• Amount Raised: $45M
• Total Raised: $67M
• Funding Stage: Series B
• Funding Date: April 14, 2026

Bluefish Raises $43M in Series B Funding for Agentic Marketing and AI Visibility Control

Bluefish sells into a fast-forming enterprise need: measuring and influencing how brands appear inside AI-mediated discovery surfaces, including conversational assistants and AI shopping agents. As generative systems become a first stop for product research, marketers are being pushed to treat AI outputs as a channel with monitoring, governance, and performance levers.

The Series B is meaningful because it signals “AI visibility,” moving from experimental spend to budgeted infrastructure for large brands. The round also illustrates a common 2026 pattern: startups that instrument AI systems—rather than building yet another model—are attracting growth-stage capital when they can tie their product to measurable business control points.

Funding Details:

• Startup: Bluefish
• Investors: Co-leads Threshold Ventures and New Enterprise Associates; notable participation from American Express Ventures, TIAA Ventures, Bloomberg Beta, and Salesforce Ventures
• Amount Raised: $43M
• Total Raised: $68M
• Funding Stage: Series B
• Funding Date: April 14, 2026

Synera Raises $40M in Series B Funding for Agentic AI in Industrial Engineering Workflows

Synera is building an orchestration layer for industrial engineering that uses AI agents to execute tasks across dozens of existing engineering tools—aiming to automate repetitive simulation, optimization, costing, and reporting work without forcing companies to rip and replace their software stack. A key differentiator is deployment posture: the platform is designed to run in customer-controlled environments, a requirement for organizations that treat design IP and manufacturing data as crown jewels.

This Series B matters because it funds expansion into the U.S. and broader enterprise-scale growth, anchored by a strategic investor that can serve as a channel partner for industrial accounts. It’s a concrete example of “agentic AI” moving beyond office workflows and into high-value engineering systems where integration depth and trust boundaries are non-negotiable.

Funding Details:

• Startup: Synera
• Investors: Lead Revaia; strategic participation from Capgemini (via ISAI Cap Venture); returning investors include UVC Partners, BMW iVentures, Cherry Ventures, Spark Capital
• Amount Raised: $40M
• Total Raised: ~ $58M
• Funding Stage: Series B
• Funding Date: April 14, 2026

Calyxo Raises $40M in Series F Funding for Kidney Stone Removal Commercial Expansion

Calyxo develops the CVAC System, an aspiration-based approach to kidney stone removal that improves stone clearance by continuously evacuating fragments during procedures. The company framed the round around adoption metrics—highlighting that 40,000 patients have been treated—and indicated that the financing is meant to support scaling and evidence generation, not just initial commercialization.

The $40 million Series F reflects a late-stage medtech pattern: capital flows to companies that can pair clinician adoption with the production of clinical and economic data. For device businesses selling into procedure-heavy specialties, expanding proof and reimbursement narratives can be as important as expanding sales teams.

Funding Details:

• Startup: Calyxo
• Investors: Leads Ally Bridge Group and Janus Henderson Investors; continued support from Questa Capital, Avidity Partners, CRG
• Amount Raised: $40M
• Total Raised: Undisclosed
• Funding Stage: Series F
• Funding Date: April 14, 2026

Spiral Therapeutics Raises $27M in Series B Funding for Inner Ear Disorder Therapeutics and Drug Delivery Platform

Spiral Therapeutics is a clinical-stage biotech developing therapies for inner ear disorders, including a lead program (SPT-2101) and a proprietary delivery platform designed for minimally invasive cochlear drug delivery. The Series B was paired with a strategic R&D collaboration to explore drug delivery at the time of cochlear implantation—an integration of therapeutics and device-adjacent workflows that can materially affect outcomes.

The significance here is strategic alignment: bringing in a cochlear implant leader and another large pharma partner suggests a path where Spiral’s clinical programs could plug into established hearing-care ecosystems. It also underscores that “platform + partnership” structures remain a viable means of funding specialized clinical programs in smaller therapeutic niches.

Funding Details:

• Startup: Spiral Therapeutics
• Investors: Lead Gund Investment Corporation; new strategic investors, Advanced Bionics and a major global pharmaceutical company; continued participation from Ferring Ventures and Uni-Bio Science Group (plus other existing investors)
• Amount Raised: $27M
• Total Raised: Undisclosed
• Funding Stage: Series B
• Funding Date: April 14, 2026

Pillar Raises $20M in Seed Funding for Automated Commodity Risk Hedging

Pillar is building automation to address a problem that many commodity-dependent businesses still rely on spreadsheets and periodic decision cycles for: hedging exposures across commodities, FX, and freight. In volatile input markets, tools that turn risk management into a continuous workflow—rather than a quarterly exercise—can directly influence margin stability and inventory decisions.

The $20 million seed round stands out for two reasons: its size is large for a Seed Round, and the investor set blends institutional capital with operator context. With $23 million raised to date, Pillar is capitalized to build integrations into messy enterprise data sources (contracts, ERP systems, operational logs) that typically slow early-stage adoption.

Funding Details:

• Startup: Pillar
• Investors: Lead Andreessen Horowitz; participation from Crucible Capital, Gallery Ventures, and Dara Khosrowshahi
• Amount Raised: $20M
• Total Raised: $23M
• Funding Stage: Seed
• Funding Date: April 14, 2026

What today’s funding signals

A clear throughline in today’s largest rounds is infrastructure for AI scale, not just applications. Three of the biggest financings—Glydways ($170M), Sygaldry ($105M Series A within a $139M total), and nEye.ai ($80M)—are fundamentally about power, throughput, and architectural constraints: moving people at scale, moving bits in data centers, or bending compute-per-watt curves.

The second theme is the operationalization of “agents” into enterprise systems where accountability matters: engineering workflows (Synera), marketing governance in AI discovery channels (Bluefish), and hedging automation in commodities (Pillar). These are not consumer chatbots; they are control layers that sit atop existing tooling and aim to turn AI from a helper into a managed production system.

Finally, biotech remains bifurcated: large, milestone-driven rounds still flow to clinical execution (Adcendo, Spiral Therapeutics), while medtech late-stage capital (Calyxo) continues to reward validated adoption plus evidence-building. In all three cases, the use of proceeds is tied to clinical expansion, partnerships, and data generation rather than broad platform storytelling.

Tech Funding Summary Table